Logo 975 Pill - orange oval
Pill with imprint Logo 975 is Orange, Oval and has been identified as Levetiracetam Extended Release 750 mg. It is supplied by Actavis Elizabeth LLC.
Levetiracetam is used in the treatment of Seizures; Epilepsy and belongs to the drug class pyrrolidine anticonvulsants. Risk cannot be ruled out during pregnancy. Levetiracetam 750 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for Logo 975
Levetiracetam Extended Release
- Imprint
- Logo 975
- Strength
- 750 mg
- Color
- Orange
- Shape
- Oval
- Availability
- Prescription only
- Drug Class
- Pyrrolidine anticonvulsants
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Actavis Elizabeth LLC
- National Drug Code (NDC)
- 00228-2975 (Discontinued)
- Inactive Ingredients
-
silicon dioxide,
hypromelloses,
polyethylene glycol 6000,
povidone,
stearic acid,
FD&C Yellow No. 6,
polyvinyl alcohol,
polyethylene glycol 3350,
ferric oxide red,
magnesium silicate,
titanium dioxide,
ferric oxide yellow
Note: Inactive ingredients may vary.
Related images for "Logo 975"
More about levetiracetam
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (423)
- Drug images
- Latest FDA alerts (5)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: pyrrolidine anticonvulsants
- Breastfeeding
- En español
Patient resources
- Levetiracetam oral/injection drug information
- Levetiracetam (Intravenous) (Advanced Reading)
- Levetiracetam (Oral) (Advanced Reading)
- Levetiracetam Extended-Release Tablets
- Levetiracetam Injection
Other brands
Keppra, Keppra XR, Spritam, Elepsia XR, ... +2 more
Professional resources
- Levetiracetam monograph
- Levetiracetam Extended Release Tablets (FDA)
- Levetiracetam Injection (FDA)
- Levetiracetam Injection, Concentrate (FDA)
- Levetiracetam Solution (FDA)
Other brands
Keppra, Keppra XR, Spritam, Elepsia XR, ... +2 more
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
